U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Development & Approval Process (CBER)
  4. 2022 Biological New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) Approvals
  1. Development & Approval Process (CBER)

2022 Biological New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) Approvals

This list reflects information regarding the applications as of the approval date. It is not updated with regard to applicant or application status changes. 

2022 Biological New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) Approvals
Tradename Indication for Use NDA Number Applicant Approval Date
Anticoagulant Sodium Citrate 4% Solution Is indicated for use only for the anticoagulation of whole blood as part of automated apheresis procedures 125750/0 CSL Plasma, Inc.
155 Medical Sciences Drive
Union, SC 29379
04/25/2022

 

 

Back to Top